Detail akcie GridAI Technologies Corp online

Business Summary: GridAI Technologies Corp., formerly Entero Therapeutics, Inc., offers a grid-edge, artificial intelligence (AI)-driven software and control platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources, including battery energy storage systems. It applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The Company also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, GridAI Technologies Corp revenues increased from $0K to $36K. Net loss applicable to common stockholders excluding extraordinary items decreased 60% to $6.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative expenses decrease of 66% to $4.8M (expense).